Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Timberlyne Therapeutics

Request full access

Transformational therapies for autoimmune diseases with CM313, a monoclonal antibody targeting CD38 for rapid, durable responses

San Diego, United StatesFounded 2025Biotech & Life Sciences

About Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapies for autoimmune diseases. The company leverages its team's extensive drug development expertise to acquire and apply best-in-class assets against compelling targets. Timberlyne's lead program, CM313, is an IgG1 monoclonal antibody with enhanced cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 modulates multiple arms of the immune system, leading to rapid and durable responses across various autoimmune diseases. Timberlyne aims to develop CM313 for a broad range of autoimmune indications, addressing significant unmet medical needs. Founded in 2024, the company has raised $180 million from leading life sciences investors to advance its mission of bringing life-changing medicines to patients. Timberlyne was formed by Mountainfield Venture Partners in partnership with Keymed Biosciences and has exclusive development and commercialization rights to CM313 worldwide, excluding greater China.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2025
Headquarters
San Diego, United States
Open positions
None listed
Dealroom signal
57.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jan 2025 $180M $720M Boyu Capital · Lilly Asia Ventures · Braidwell · Venrock Healthcare Capital Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Timberlyne Therapeutics website traffic

Latest recorded traffic for Timberlyne Therapeutics is 1.1K monthly website visits, down 15.4% over the last three months.

Latest monthly visits1.1K 3-month web change-15.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Timberlyne Therapeutics in the San Diego ecosystem

Live from Dealroom

The Timberlyne Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Venrock Healthcare Capital Partners
  • Abingworth
  • Bain Capital Life Sciences
  • Boyu Capital
  • Lilly Asia Ventures
  • Braidwell
  • 3H Health Investment
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States87.5%
🇬🇧 United Kingdom12.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Timberlyne Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Timberlyne Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.